-
dedup_wf_001--0b290ab8163c03c1b59153b3ad16da48
Additional file 7: Figure S5. The morphological characteristics of the stems of d2014 and WT. -
dedup_wf_001--feb2894c60aa291b78385d84b2b7d001
Description of data: Non-pharmaceutical curative second-line procedures performed for PPH > 1000 mL. (DOCX 19 kb) -
dedup_wf_001--1267f88dc9dab84c2df43cf8151d0f07
Mass spectrometry analysis of rhSIRPA protein. Table S2. Mass spectrometry analysis of calibrator from SIRPA ELISA kit (Cusabio). Table S3. Mass spectrometry analysis of... -
Additional file 1: of Rationale and development of a business case for antimi...
Appendix A. List of search terms for legislative requirements and human resource staffing requirements in antimicrobial stewardship programs. (DOCX 18 kb) -
dedup_wf_001--392f4c72af42e16ca1668efb6e5edcac
Table S3. Summary of adverse events reported in patients who started treatment at or after Hunter Outcome Survey (HOS) entry (DOCX 25 kb) -
Additional file 2 of Effectiveness of omalizumab in patients with severe alle...
Additional file 2: Figure S2. Efficacy comparison of outcome parameters at baseline and 12 months after omalizumab treatment in patients with chronic rhinosinusitis with nasal... -
Additional file 1: of Stakeholdersâ views on the ethical challenges of prag...
Characteristics of the Salford Lung Study (GSK, UK) [24]. (DOC 25 kb) -
MOESM4 of Peripheral neuropathy in metachromatic leukodystrophy: current stat...
Additional file 4: Table S3. Ongoing clinical trials on metachromatic leukodystrophy (MLD). A summary of the ongoing clinical trials on treatment for metachromatic... -
dedup_wf_001--45f0f2c7b561a4fecc8f65ee62fee924
Objective: Dimethyl sulfide (DMS, CAS 75-18-3) is an industrial chemical. It is both an irritant and neurotoxicant that may be life-threatening because of accidental release.... -
The Pricing of Tail Risk and the Equity Premium: Evidence From International ...
We explore the pricing of tail risk as manifest in index options across international equity markets. The risk premium associated with negative tail events displays persistent... -
Additional file 2: of Post-marketing withdrawal of 462 medicinal products bec...
Web 2. Medline search strategy for identification of report dates for first report of adverse drug reaction or first date of withdrawal. (PDF 181 kb) -
dedup_wf_001--3cd3b7aae9241e85ad527b9fb51b5ea7
Reported efficacy and predicted egg reduction rate by age group and site, PZQ 40Â mg/kg. (DOCX 32 kb) -
dedup_wf_001--3071be5b2d8184c69dc09d89061ebb8d
Comparison of TO efficacy with acetylsalicylic acid (ASA). HUVECs were pretreated with TO (100 μg/ml) or different concentrations of ASA for one hour, and then stimulated with 1... -
dedup_wf_001--deb3eef117264a1d676b0cf8945cf429
List of excluded or unobtainable studies. (DOCX 15 kb) -
Additional file 5: of Evidence use in decision-making on introducing innovati...
Focus group reporting. (DOCX 115Â kb) -
dedup_wf_001--e47ec1e4cd68e401cb6460e3bfcb3df0
Trial Steering Committee (TSC) membership. (DOCX 23 kb) -
dedup_wf_001--264a8074157f2ce880fcd5feea71deab
List of Institutional Review Boards (IRB) and Independent Ethics Committees (IEC). (DOCX 13Â kb) -
Additional file 1: of Severe asthma features in children: a caseâ control on...
Criteria for exclusion of children with severe asthma and non-severe persistent asthma. (PDF 11Â kb) -
Additional file 1: of Prophylactic antibiotic use in pediatric patients under...
Antibiotic use in Pediatric Urology. This supplemental material contains the full survey sent out to members of the SPU. (DOCX 23Â kb) -
Additional file 3: of Achieving Good Outcomes for Asthma Living (GOAL): mixed...
Provides a breakdown of health service resource use costs in the intervention and control groups. (DOCX 53 kb)
